Stockreport

Travere Therapeutics 2026 Outlook: Filspari Momentum, FSGS FDA Delay, And Market Potential [Seeking Alpha]

Travere Therapeutics, Inc.  (TVTX) 
PDF Filspari's label expansion for FSGS faces a three-month FDA review delay, due to mixed DUPLEX trial efficacy, introducing regulatory risk. TVTX's valuation reflects r [Read more]